Context Therapeutics Appoints Andy Pasternak as Chairman of the Board of Directors

Core Insights - Context Therapeutics Inc. has appointed Andy Pasternak as the new Chairman of its Board of Directors, succeeding Richard Berman, effective January 12, 2025, marking a significant transition in leadership to guide the company into its next growth phase [1][3] Company Overview - Context Therapeutics is a biopharmaceutical company focused on advancing T cell engaging bispecific antibodies for solid tumors, with a portfolio that includes CTIM-76, CT-95, and CT-202 [4] Leadership Experience - Andy Pasternak brings over 25 years of experience in the biopharmaceutical industry, previously serving as Executive Vice President and Chief Strategy Officer at Horizon Therapeutics, where he played a key role in the $28 billion acquisition by Amgen in 2023 [2] - Pasternak's background includes significant roles at Bain & Company, where he was Head of the Healthcare Practice in the Americas, and he currently serves on the Board of Directors of Endo, Inc. [2] Strategic Vision - Pasternak expressed his commitment to leveraging his experience to help Context continue to innovate in the rapidly evolving field of T cell engagers, aiming to improve patient outcomes [2]